ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.

Munenobu KashiwaPubMed ↗Publisher ↗

No numbers read from the abstract.